{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:29:10Z","timestamp":1792250950221,"version":"4.4.0"},"reference-count":62,"publisher":"Michigan State University College of Osteopathic Medicine Statewide Campus System","issue":"3","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec id=\"introduction\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC) is a chronic inflammatory bowel disorder (IBD) with periods of relapse and remission. Current advancements in clinical research have led to the development of more refined and effective medical therapy for UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"summary-of-the-evidence\">\n                    <jats:title>Summary of the Evidence<\/jats:title>\n                    <jats:p>Traditional therapeutic agents such as 5-aminosalicylates (5-ASAs), sulfasalazine (SASP), corticosteroids, and immunomodulatory drugs have remained the gold standard for decades. However, their novel formulations and dosage regimens have changed their sequences in the medical management of UC. Several other novel drugs are in the final phases of clinical development or have recently received regulatory approval designed to target specific mechanisms involved in the inflammatory cascade for UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This narrative review sought to provide a comprehensive knowledge of the potential benefits of standard and emerging therapies, including novel formulations, new chemical entities, and novel therapeutic approaches in managing UC.<\/jats:p>\n                    <jats:p>Keywords: Ulcerative colitis, 5- Aminosalicylic acid, sulfasalazine, corticosteroids, biologics, immunomodulators, novel formulations<\/jats:p>\n                  <\/jats:sec>","DOI":"10.51894\/001c.123397","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T13:07:40Z","timestamp":1726232860000},"source":"Crossref","is-referenced-by-count":28,"title":["Current Pharmacologic Options and Emerging Therapeutic Approaches for the Management of Ulcerative Colitis: A Narrative Review"],"prefix":"10.51894","volume":"9","author":[{"given":"Sneha Annie","family":"Sebastian","sequence":"first","affiliation":[{"name":"Edgemont Medical Centre, Calgary, Canada","department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oroshay","family":"Kaiwan","sequence":"additional","affiliation":[{"name":"Northeast Ohio Medical University, USA","department":["Department of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edzel L.","family":"Co","sequence":"additional","affiliation":[{"name":"University of Santo Tomas, Manila","department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Mehendale","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine","department":["Smolensk State Medical University, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu P.","family":"Mohan","sequence":"additional","affiliation":[{"name":"University of Utah School of Medicine, Utah, USA","department":["Department of Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"29343","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3390\/jcm11040939","article-title":"Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art","volume":"11","author":"E. Vespa","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"ref2","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/gutjnl-2018-316702","article-title":"Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomized controlled trial","volume":"68","author":"V. Jairath","year":"2019","journal-title":"Gut"},{"issue":"3","key":"ref3","doi-asserted-by":"publisher","first-page":"e0248224","DOI":"10.1371\/journal.pone.0248224","article-title":"Real-life evaluation of histologic scores for Ulcerative Colitis in remission","volume":"16","author":"C. B. Arkteg","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"ref4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/apt.15568","article-title":"Complete histologic normalization is associated with reduced risk of relapse among patients with ulcerative colitis incomplete endoscopic remission","volume":"51","author":"K. C. Cushing","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"ref5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ajg.2016.50","article-title":"Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study","volume":"111","author":"T. Zenlea","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"26","key":"ref6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"K. W. Schroeder","year":"1987","journal-title":"N Engl J Med"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.gtc.2020.08.003","article-title":"Assessing Severity of Disease in Patients with Ulcerative Colitis","volume":"49","author":"B. S. Pabla","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"CD011450","DOI":"10.1002\/14651858.CD011450.pub2","article-title":"Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis","volume":"1","author":"N. Mohammed Vashist","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ref9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/gutjnl-2016-312648","article-title":"Development of an index to define overall disease severity in IBD","volume":"67","author":"C. A. Siegel","year":"2018","journal-title":"Gut"},{"issue":"6","key":"ref10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"J. Satsangi","year":"2006","journal-title":"Gut"},{"issue":"8 Spec No.","key":"ref11","first-page":"SP303","article-title":"5-ASA to sulfasalazine drug switch program in patients with ulcerative colitis","volume":"24","author":"J. R. Goldsmith","year":"2018","journal-title":"The American journal of managed care"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: Ulcerative Colitis in Adults","volume":"114","author":"D. T. Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e000103","DOI":"10.1136\/bmjgast-2016-000103","article-title":"Usefulness of sulfasalazine for patients with refractory ulcerative colitis","volume":"3","author":"T. Yoshino","year":"2016","journal-title":"BMJ Open Gastro"},{"issue":"12","key":"ref14","first-page":"137","article-title":"Relative effectiveness of aminosalicylates in the management of acute ulcerative colitis - Mesalamine vs Sulfasalazine","volume":"3","author":"Syed Ibrahim Hassan","year":"2016","journal-title":"IAIM"},{"issue":"12","key":"ref15","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3390\/jcm8122109","article-title":"Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents","volume":"8","author":"E. Yasutomi","year":"2019","journal-title":"Journal of clinical medicine"},{"issue":"26","key":"ref16","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1056\/nejm198012253032602","article-title":"Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn\u2019s disease","volume":"303","author":"U. Klotz","year":"1980","journal-title":"New England Journal of Medicine"},{"issue":"s3","key":"ref17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2036.2006.03058.x","article-title":"Review article: High-dose aminosalicylates to induce and maintain remissions in ulcerative colitis","volume":"24","author":"S. B. Hanauer","year":"2006","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"ref18","first-page":"893","article-title":"The role of mesalamine in the treatment of ulcerative colitis","volume":"3","author":"R. Karagozian","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"ref19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1155\/2010\/586092","article-title":"Mesalazine in inflammatory bowel disease: A trendy topic once again?","volume":"24","author":"M. Iacucci","year":"2010","journal-title":"Can J Gastroenterol"},{"issue":"7","key":"ref20","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/j.1572-0241.2004.40036","article-title":"Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee","volume":"99","author":"A. Kornbluth","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"ref21","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/j.1572-0241.2005.00248","article-title":"Delayed-release oral mesalamine at 4.8 g\/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial","volume":"100","author":"S. B. Hanauer","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"ref22","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.gtc.2006.09.001","article-title":"Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab","volume":"35","author":"A. Barrie","year":"2006","journal-title":"Gastroenterology clinics of North America"},{"issue":"3","key":"ref23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00325481.2016.1152876","article-title":"Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors","volume":"128","author":"S. F. Zakko","year":"2016","journal-title":"Postgrad Med"},{"issue":"4","key":"ref24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.gtc.2020.07.002","article-title":"Mesalamine in the Initial Therapy of Ulcerative Colitis","volume":"49","author":"R. Chibbar","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"issue":"35","key":"ref25","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.3748\/wjg.15.4353","article-title":"5-ASA in ulcerative colitis: improving treatment compliance","volume":"15","author":"C. Prantera","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"6","key":"ref26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1517\/14656566.9.6.1049","article-title":"MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis","volume":"9","author":"M. Y. Hu","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"ref27","first-page":"7","article-title":"Once-daily MMX mesalamine in the management of ulcerative colitis","author":"Wojciech Blonski","year":"2011","journal-title":"Clinical Medicine Insights: Gastroenterology"},{"issue":"6","key":"ref28","first-page":"514","article-title":"Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease","volume":"11","author":"L. W. Segars","year":"1992","journal-title":"Clin Pharm"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/00365528809101539","article-title":"Pharmacology of olsalazine","volume":"148","author":"D. E. Campbell","year":"1988","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"4","key":"ref30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2165\/00003495-199141040-00009","article-title":"Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease","volume":"41","author":"A. N. Wadworth","year":"1991","journal-title":"Drugs"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3109\/00365528809101553","article-title":"Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects","volume":"148","author":"K. Ewe","year":"1988","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"8","key":"ref32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1046\/j.1365-2036.1998.00360.x","article-title":"Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis","volume":"12","author":"W. Kruis","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"ref33","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1053\/j.gastro.2008.09.053","article-title":"Current Directions in IBD therapy: what goals are feasible with biological modifiers?","volume":"135","author":"W. J. Sandborn","year":"2008","journal-title":"Gastroenterology"},{"issue":"11","key":"ref34","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2165\/00003495-200262110-00010","article-title":"Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis","volume":"62","author":"R. B. Muijsers","year":"2002","journal-title":"Drugs"},{"issue":"10","key":"ref35","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1517\/17425250903206996","article-title":"Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis","volume":"5","author":"J. B. Wiggins","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"ref36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003495-199856010-00008","article-title":"Balsalazide","volume":"56","author":"A. Prakash","year":"1998","journal-title":"Drugs"},{"issue":"2","key":"ref37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.0269-2813.2004.01827.x","article-title":"Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis","volume":"19","author":"E. V., Jr. Loftus","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"ref38","article-title":"Fact Sheet :News from the IBD Help Center: Aminosalicylates","year":"2018"},{"issue":"17","key":"ref39","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.2165\/00003495-200767170-00010","article-title":"Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis","volume":"67","author":"P. L. McCormack","year":"2007","journal-title":"Drugs"},{"issue":"4","key":"ref40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1586\/eci.10.22","article-title":"Once-daily mesalamine granules for ulcerative colitis","volume":"6","author":"G. Lawlor","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"ref41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0016-5085(90)91237-z","article-title":"Long-term use of mesalamine enemas to induce remission in ulcerative colitis","volume":"99","author":"W. L. Biddle","year":"1990","journal-title":"Gastroenterology"},{"issue":"5","key":"ref42","first-page":"309","article-title":"Advantages in IBD: Current Developments in the Treatment of Inflammatory Bowel Diseases","volume":"6","author":"Stephen B. Hanauer","year":"2010","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"11","key":"ref43","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/ibd.21256","article-title":"Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents","volume":"16","author":"M. B. Heyman","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"ref44","doi-asserted-by":"publisher","first-page":"CD000543","DOI":"10.1002\/14651858.CD000543","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","author":"L. Sutherland","year":"2003","journal-title":"The Cochrane database of systematic reviews"},{"issue":"4","key":"ref45","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"A.C. Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"ref46","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.mayocp.2014.07.002","article-title":"Ulcerative colitis: epidemiology, diagnosis, and management","volume":"89","author":"J. D. Feuerstein","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"ref47","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis","volume":"158","author":"S. Singh","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"ref48","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/apt.17386","article-title":"Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis","volume":"57","author":"C. Taxonera","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"ref49","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00535-019-01651-0","article-title":"Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial","volume":"55","author":"M. Naganuma","year":"2020","journal-title":"J Gastroenterol"},{"issue":"3","key":"ref50","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis","volume":"156","author":"C. W. Ko","year":"2019","journal-title":"Gastroenterology"},{"issue":"8","key":"ref51","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.12998\/wjcc.v8.i8.1361","article-title":"Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases","volume":"8","author":"F. S. Cheng","year":"2020","journal-title":"World J Clin Cases"},{"issue":"14","key":"ref52","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3748\/wjg.v29.i14.2078","article-title":"Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives","volume":"29","author":"S. Roy","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"4","key":"ref53","doi-asserted-by":"publisher","first-page":"otaa067","DOI":"10.1093\/crocol\/otaa067","article-title":"Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy","volume":"2","author":"A. Sood","year":"2020","journal-title":"Crohns Colitis 360"},{"issue":"1","key":"ref54","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2015.03.045","article-title":"Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis","volume":"149","author":"N. G. Rossen","year":"2015","journal-title":"Gastroenterology"},{"issue":"12","key":"ref55","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3390\/jcm8122109","article-title":"Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents","volume":"8","author":"E. Yasutomi","year":"2019","journal-title":"Journal of clinical medicine"},{"issue":"1","key":"ref56","doi-asserted-by":"publisher","first-page":"14494","DOI":"10.1038\/s41598-023-41182-6","article-title":"Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis","volume":"13","author":"J. Feng","year":"2023","journal-title":"Sci Rep"},{"issue":"8","key":"ref57","doi-asserted-by":"publisher","first-page":"e233135","DOI":"10.1136\/bcr-2019-233135","article-title":"Faecal microbiota transplantation (FMT) with dietary therapy for acute severe ulcerative colitis","volume":"13","author":"S. P. Costello","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"1","key":"ref58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/apt.16148","article-title":"Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020","volume":"53","author":"C. Marcella","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.03069.x","article-title":"Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence","volume":"24 Suppl 1","author":"P. Desreumaux","year":"2006","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"1","key":"ref60","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11938-014-0044-5","article-title":"Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?","volume":"13","author":"E. Y. Ho","year":"2015","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"6","key":"ref61","doi-asserted-by":"publisher","first-page":"874","DOI":"10.14309\/ajg.0000000000000183","article-title":"A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review","volume":"114","author":"R. Ungaro","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"10080","key":"ref62","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"R. Ungaro","year":"2017","journal-title":"Lancet"}],"container-title":["Spartan Medical Research Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/smrj.scholasticahq.com\/article\/123397-current-pharmacologic-options-and-emerging-therapeutic-approaches-for-the-management-of-ulcerative-colitis-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T13:57:53Z","timestamp":1757944673000},"score":1,"resource":{"primary":{"URL":"https:\/\/smrj.scholasticahq.com\/article\/123397-current-pharmacologic-options-and-emerging-therapeutic-approaches-for-the-management-of-ulcerative-colitis-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":62,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.51894\/001c.123397","relation":{},"ISSN":["2474-7629"],"issn-type":[{"value":"2474-7629","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]}}}